Mizuho Securities Co. Ltd. Increases Stake in Pfizer Inc. (NYSE:PFE)

Mizuho Securities Co. Ltd. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 261.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,700 shares of the biopharmaceutical company’s stock after buying an additional 2,677 shares during the period. Mizuho Securities Co. Ltd.’s holdings in Pfizer were worth $107,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Investment Advisory Services Inc. TX ADV boosted its position in shares of Pfizer by 1.6% during the third quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock valued at $667,000 after purchasing an additional 325 shares in the last quarter. Trifecta Capital Advisors LLC lifted its holdings in shares of Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 325 shares in the last quarter. Powers Advisory Group LLC lifted its holdings in shares of Pfizer by 2.4% during the third quarter. Powers Advisory Group LLC now owns 13,759 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 329 shares in the last quarter. Confluence Wealth Services Inc. lifted its holdings in shares of Pfizer by 0.5% during the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after purchasing an additional 342 shares in the last quarter. Finally, Carr Financial Group Corp increased its position in Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 355 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Finally, Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Stock Performance

Shares of PFE traded up $0.06 during midday trading on Tuesday, reaching $26.32. 24,286,365 shares of the stock were exchanged, compared to its average volume of 42,105,117. The business’s 50-day moving average price is $27.07 and its 200 day moving average price is $28.52. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37. The company has a market capitalization of $149.04 billion, a price-to-earnings ratio of 73.11, a PEG ratio of 1.17 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the company posted $1.14 earnings per share. The business’s revenue was down 41.3% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.